Cargando…

FDA initiatives to support dose optimization in oncology drug development: the less may be the better

Detalles Bibliográficos
Autor principal:	Moon, Hanlim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society for Clinical Pharmacology and Therapeutics 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9253446/ https://www.ncbi.nlm.nih.gov/pubmed/35800667 http://dx.doi.org/10.12793/tcp.2022.30.e9

Ejemplares similares

Expert clinical consulting for early drug development programs in Korea
por: Moon, Hanlim
Publicado: (2019)

Clinical Trial Diversity in Oncology: FDA Takes Action with Post–Marketing Requirements or Commitments
por: Kim, Janice, et al.
Publicado: (2022)

Clinical studies involving probiotics: When FDA’s investigational new drug rubric applies—and when it may not
por: Degnan, Fred H.
Publicado: (2012)

The FDA Changed Everything
por: Geantă, Marius, et al.
Publicado: (2017)

Nuclear Factor One X Mice model for Malan syndrome: the less the better
por: Priolo, Manuela
Publicado: (2018)

Can an FDA-Approved Alzheimer’s Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika Virus?
por: Sirohi, Devika, et al.
Publicado: (2017)

The Current State of Pharma and the FDA: Approval of a Dementia Drug as a Case in Point
por: Eiser, Arnold R.
Publicado: (2021)

Caffeine and Bones: If Less Is Good, More May Not Be Better
por: Antonioli, Luca, et al.
Publicado: (2019)

Deciphering the vedolizumab dosing conundrum in IBD: when less is more
por: Adolph, Timon Erik, et al.
Publicado: (2022)

Assessing the Benefit-Risk for New Drugs: Are the FDA's Endocrinologic and Metabolic Drugs Advisory Committee and the Division of Metabolism and Endocrinology Products in sync?
por: Brass, Eric P.
Publicado: (2013)

Quality Oncology Practice Initiative Can Guide and Improve Oncology Providers’ Training in Brazil
por: Bergerot, Cristiane Decat, et al.
Publicado: (2016)

Molecular functional imaging in personalized clinical oncology: The road less traveled
por: Mahajan, Abhishek, et al.
Publicado: (2016)

Re-orienting anti-malarial drug development to better serve pregnant women
por: El Gaaloul, Myriam, et al.
Publicado: (2022)

Doxorubicin Dose Deintensification in Pediatric Osteosarcoma, Is Less Better?
por: Halalsheh, Hadeel, et al.
Publicado: (2023)

Reduced fertility from better access to contraception may not improve women’s health
por: Lam, David
Publicado: (2021)

The menacing assaults on science, FDA, CDC, and health of the US public
por: Alter, Scott M., et al.
Publicado: (2020)

Tranexamic acid: less bleeding and less thrombosis?
por: Godier, Anne, et al.
Publicado: (2012)

Better drugs for Lyme disease: focus on the spirochete
por: Stricker, Raphael B, et al.
Publicado: (2018)

Commentary: Anastomoses for esophagectomy: Surgeons may always know which is the better option for themselves
por: Li, Bin, et al.
Publicado: (2021)

FDA relations during drug development
por: Mitchel, Jules T.
Publicado: (2000)

FDA and Its Role in Drug Development
por: Pazdur, Richard
Publicado: (2021)

A Guide for Oncologic Patient Management during Covid-19 Pandemic: The Initial Experience of an Italian Oncologic Hub with Exemplificative Focus on Uro-Oncologic Patients
por: Mistretta, Francesco A., et al.
Publicado: (2020)

Dose Optimization in Oncology Drug Development: The Emerging Role of Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics
por: Papachristos, Apostolos, et al.
Publicado: (2023)

CARE program: NCI and FDA interagency collaborations to support oncology small business entrepreneurs
por: Pond, Monique A., et al.
Publicado: (2023)

Non-in situ heart-lung transplantation: doing less may prove to be worth it
por: Thomas, Jason O. A., et al.
Publicado: (2021)

The FDA guidance for industry on PROs: the point of view of a pharmaceutical company
por: Arpinelli, Fabio, et al.
Publicado: (2006)

Safeguarding evidence-based decision making in the FDA for COVID-19 vaccines
por: Angelis, Aris, et al.
Publicado: (2021)

Monkeypox, smallpox, FDA, and accelerated approval of vaccines – A regulatory perspective
por: Sun, Wellington
Publicado: (2023)

The dose of inhaled corticosteroids in patients with COPD: when less is better
por: Izquierdo, José Luis, et al.
Publicado: (2018)

The FDA initiatives for personalized medicine
por: Wolfe, Olive Joy
Publicado: (2014)

Too early initiation of renal replacement therapy may be harmful
por: Vinsonneau, Christophe, et al.
Publicado: (2011)

FDA's pathway for regulation of FMT: not so fraught
por: Riley, Margaret F., et al.
Publicado: (2015)

Feedback on the FDA's February 2006 draft guidance on Patient Reported Outcome (PRO) measures from a developer of PRO measures
por: Bradley, Clare
Publicado: (2006)

Project Optimus, an FDA initiative: Considerations for cancer drug development internationally, from an academic perspective
por: Murphy, Ravindhi, et al.
Publicado: (2023)

Potential repurposing of oncology drugs for the treatment of Alzheimer's disease
por: Araki, Wataru
Publicado: (2013)

Commentary: Better late than never to optimize pain management in cardiac surgery
por: Grant, Michael C.
Publicado: (2022)

Mechanical circulatory support for shock: A little bit better is just not enough!
por: Karami, M., et al.
Publicado: (2020)

Nutritional support in sepsis: when less may be more
por: van Niekerk, Gustav, et al.
Publicado: (2020)

Since the Mid-2010s FDA Drug and Biologic Guidelines have been Growing at a Faster Clip than Prior Years: Is it Time to Analyze Their Effectiveness?
por: Daizadeh, Iraj
Publicado: (2020)

Impact of age on optimal dose of antidepressants
por: Hashimoto, Kenji
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_206ea45a46vdojtbd1r73o7rdt